Representation of Life Sciences Company Fagron Holding USA LLC

We served as lead counsel representing a national pharmaceutical ingredient supplier and its wholly-owned subsidiaries in an investigation of alleged False Claims Act (FCA) violations concerning inflated Average Wholesale Prices, kickbacks to physicians, and waivers of co-pays.  After a several-year investigation based on the filing of four separate qui tams, we negotiated a successful resolution of the litigation that was far less than the government’s alleged damages of several hundred million dollars. Reported decision: U.S. ex rel. Hueseman v. PSI et al., (WDTX) and U.S. ex rel. Sten v. Midwest Compounders, et al., (NDIA). 

You Also May Be Interested In:

  • Advise a public university system on compliance with the rules associated with grants and contracts from NIH, NSF, and the Department of Defense

    We advise a public university system on compliance with the rules associated with grants and contracts from NIH, NSF, and...
    Client Type: Nonprofit
  • Representation of Parthenon Capital, a growth-oriented private equity firm, as healthcare regulatory counsel in its investment in RxSense, a high-growth healthcare technology company that utilizes its proprietary technology platform to provide innovative prescription savings solutions to consumers and pharmacy benefits administration and analytics to enterprise customers

    We served as healthcare regulatory counsel to Parthenon Capital, a growth-oriented private equity firm, in its investment in RxSense, a...
    Client Type: Private Company
  • Representation of Lead Capital Partners, a multi-family sponsored private equity firm, in its acquisition of Ladd Dental Group, Inc., a dental service provider with six locations throughout central Indiana

    We represented Lead Capital Partners, a multi-family sponsored private equity firm, in its acquisition of Ladd Dental Group, Inc., a...
    Client Type: Private Company